ArticleMolecules (Basel, Switzerland)2020
A Series of Isatin-Hydrazones with Cytotoxic Activity and CDK2 Kinase Inhibitory Activity: A Potential Type II ATP Competitive Inhibitor.
Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 44 citations in OpenAlex.
- Hydrazone-heterocyclic hybrids as promising anticancer agents: a comprehensive review.RSC advances · 2026Review
- Targeting bacitracin resistance-associated histidine kinase (BraS) in MRSA with isatin and indazole derivatives.Scientific reports · 2026Article
- Biological evaluations and biomolecular interactions along with computational insights of arylidene isatin hydrazones synthesized using nanocatalyst.Scientific reports · 2025Article
- A comprehensive review and recent advances on isatin-based compounds as a versatile framework for anticancer therapeutics (2020-2025).RSC advances · 2025Review
- Design and Synthesis of New 5-Methylisatin Derivatives as Potential CDK2 Inhibitors.International journal of molecular sciences · 2025Article
- Article
- Molecular docking and synthesis of N-alkyl-isatin-3-imino aromatic amine derivatives and their antileishmanial and cytotoxic activities.Research in pharmaceutical sciences · 2024Article
- Identification of dual-target isoxazolidine-isatin hybrids with antidiabetic potential: Design, synthesis,Heliyon · 2024Article
- Evaluation of Anti-Neuroinflammatory Activity of Isatin Derivatives in Activated Microglia.Molecules (Basel, Switzerland) · 2023Article
- Antidiabetic and Anticancer Potentials ofPharmaceuticals (Basel, Switzerland) · 2023Article
- Biological Screening ofPharmaceuticals (Basel, Switzerland) · 2022Article
- Anticancer Inhibitors.Molecules (Basel, Switzerland) · 2022Article
- Evaluation of antioxidant and cytotoxic properties of phenolicRoyal Society open science · 2022Article
- Characterization of Promising Cytotoxic Metabolites fromPlants (Basel, Switzerland) · 2022Article
- Co-Inhibition of P-gp and Hsp90 by an Isatin-Derived Compound Contributes to the Increase of the Chemosensitivity of MCF7/ADR-Resistant Cells to Doxorubicin.Molecules (Basel, Switzerland) · 2021Article
- Quinazolin-4(3Journal of enzyme inhibition and medicinal chemistry · 2021Article
- NovelInternational journal of molecular sciences · 2021Article
- Inversion kinetics of someRSC advances · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Isatin derivatives potentially act on various biological targets. In this article, a series of novel isatin-hydrazones were synthesized in excellent yields. Their cytotoxicity was tested against human breast adenocarcinoma (MCF7) and human ovary adenocarcinoma (A2780) cell lines using MTT assay. Compounds
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.